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Photo: Courtesy of Bill Kimbel.The benefit could also apply to 
amyotrophic lateral sclerosis (ALS). 
While the mechanism by which the 
gene therapy triggers these beneficial 
effects remains to be elucidated, this 
unexpected finding suggests that 
even gene therapy for rare specific 
gene defects may in some cases have 
broader applicability. 
Recent developments have 
broadened the scope of gene 
therapy beyond the small group of 
simple diseases caused by a single 
gene defect. As outlined above, the 
possibility to introduce apoptosis 
genes into specific cells has opened 
up applications in cancer therapy. The 
company that got the first regulatory 
approval for gene therapy, uniQure, 
also has advanced development 
programmes targeting diseases like 
intermittent porphyria, Sanfilippo B, 
hemophilia B and Parkinson’s disease. 
Surprisingly, even patients with 
infectious diseases can benefit from 
gene therapy. Efforts are underway to 
use a rare gene variant that makes some 
people immune to HIV in the treatment 
of patients who have contracted the 
virus. An initial experimental treatment 
of a patient with leukaemia and HIV 
who received a bone marrow transplant 
from a donor with the resistance gene 
variant suggested that the idea works 
in principle, but that a less invasive 
implementation needs to be found. 
In March this year, researchers 
reported first results of a phase I 
clinical study based on ex vivo gene 
editing to introduce the HIV-resistant 
trait into a population of lymphocytes 
which were then re-injected to the 
patients. While the trial was designed 
only to establish the safety, not the 
efficacy of the treatment, observations 
were encouraging, as several patients 
were able to keep the virus in check 
without their usual daily drugs (N. Engl. 
J. Med. (2014) 370, 901–910). 
The broad range of success stories 
emerging in the last few years has 
given researchers in the field fresh 
optimism, mirrored also in the activity 
of biotech entrepreneurs and venture 
capital firms. In spite of its troubled 
beginnings, it looks like gene therapy 
is now set to take up a significant role 
in clinical practice, fulfilling treatment 
needs that have proven elusive to 
conventional therapies. 
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Why did you initially choose medicine 
as a career? I was hopeless at 
languages — I had a debilitating 
stammer — and in those days you 
learned languages by reading out loud 
from a book and that was beyond 
me. But I was reasonably good at 
science and geography. My method 
for finding a possible career was 
unconventional but practical. My 
parents owned a grocery store. One of 
my chores was to deliver groceries on 
a bicycle. In general, when I delivered 
groceries to the houses of lawyers 
and accountants, I felt my efforts were 
unappreciated. There was, however, 
a medical household where I would 
always be given a glass of lemonade, 
and where my nascent interest in 
medicine was encouraged — Bill Clark 
even gave me his copy of a book of 
essays by Sir William Osler. It is still 
on my bookshelf. His kindness and 
solicitude are why I decided to become 
a doctor.
Why did you switch to 
paleoanthropology? There were 
elements of ‘push’ and ‘pull’: the ‘push’ 
was that I had the good fortune to 
be apprenticed to a surgeon whose 
diagnostic and clinical skills were 
legendary. However, he was so good 
that it was pretty clear to me that, 
no matter hard I worked at it, I was 
unlikely to be as good a surgeon as 
he was. And what was the point of 
doing something like surgery if you 
Q & Acould not be among the best? The 
‘pull’ was my enjoyment of human 
anatomy, combined with the realization 
that because of my good fortune to 
be involved with Richard Leakey’s 
research team, I had the unique 
opportunity to help interpret the new 
evidence they were unearthing.
Why did you choose to work on skulls 
and teeth? I didn’t. I was one of three 
anatomists (the others were Michael 
Day and Alan Walker) Richard Leakey 
had invited to describe and interpret 
the hominin fossils recovered from Lake 
Rudolf. The majority of the fossils were 
from the skull and dentition, but each of 
us wanted to work on the limb bones. 
In 1972, we met in New York to discuss 
the impasse, but none of us would give 
in. So, not a little frustrated, Richard 
broke three matches into different 
lengths and made us draw. Mine was 
the shortest match, so I had no choice 
but to work on the cranial remains. This 
task, which involved determining how 
many taxa were represented among the 
hominin cranial fossils, led to the topic 
of my PhD, sexual dimorphism, and 
my interest in patterns of intra- versus 
interspecific variation. 
What do you enjoy most about being 
a paleoanthropologist? I have a 
passionate dislike of games of chance, 
but I do like solving real-life puzzles. 
All paleontology is challenging, but 
because we are trying to reconstruct 





 such a fine scale, it is especially 
challenging. I get bored too easily, 
and paleoanthropology provides a 
seemingly unlimited opportunity to 
explore the potential of exciting topics, 
such as evo-devo, to help reduce our 
ignorance about human evolutionary 
history. 
What features do you most admire 
in your colleagues? Intellectual 
horsepower coupled with generosity, 
humility and a sense of humor.
What features do you least admire in 
your colleagues? Self-righteousness, 
an unjustified sense of self-importance, 
a lack of generosity and the inability 
to laugh at yourself. In my experience, 
these traits are highly correlated.
Do you have a scientific hero? That’s 
a difficult one. The colleague I admire 
most for lots of reasons is the late 
Glynn Isaac, who was an archaeologist, 
not a paleoanthropologist. Glynn 
recognized that in the absence of the 
right careful and thoughtful research 
questions, even if you were drowning 
in data, you would be none the wiser. 
If you had a scientific fairy godfather 
what question would you ask him? 
Please, how do you detect homoplasy 
in the hominin fossil record?
If you had a time machine, how far 
would you ask to go back, where 
would you go, and what would you 
want to see? Two million years ago, 
the Turkana Basin in East Africa. 
I would want to follow groups of 
Paranthropus boisei and Homo habilis 
to see what they ate, how they moved, 
what their social structure was like and 
how they used the landscape in good 
times and bad.
If not a paleoanthropologist, then 
what? Either a conductor, or a 
classical pianist. I greatly admire 
the late Claudio Abbado, both as a 
musician, and as a human being. I 
would trade all my publications for 
one of Abbado’s performances of 
Bruckner’s 9th Symphony, or to be 
able to play J.S. Bach’s Partita No. 4 D 
major (BMV 828) like Murray Perahia. 
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What are strigolactones? 
Strigolactones are a family of small 
organic compounds with a four-ring 
structure as simple as ‘ABCD’. The 
ABC rings carry one lactone and the 
D ring another lactone (often called 
the butenolide, just to confuse the 
non-chemists; Figure 1A). There are 
many types of strigolactones and 
different species may have different 
representatives.
Where did the name come from? 
Well the lactone part obviously came 
from the structure and the ‘striga’ 
part came from their first identified 
function. They were originally 
identified as very annoying molecules 
exuded from plant roots because they 
stimulated germination of very harmful
parasitic weeds, such as Striga sp. 
and Orobanche sp. The term ‘striga’ 
comes from the Latin words strix or 
strigis, which mean witch or evil spirit.
How were they discovered? As 
you may have already guessed, 
strigolactones were discovered as 
being the molecule perceived by 
parasitic weeds such as Striga to 
recognise the close proximity to a 
compatible root. Strigolactones exuded
into the rhizosphere were later found 
to enhance the symbiotic relationship 
with arbuscular mycorrhizae (AM 
fungi), common in around 80% of land 
plants and which improves nutrient and
water uptake by plants. 
While these discoveries were 
occurring in the underworld, the above
ground had its own mystery; a long-
distance hormone controlling shoot 
branching was evading discovery. In a
perfect example of ‘a day in the library
is worth months in the lab’, these 
stories collided with the discovery 
that the shoot-branching hormone 
was derived from the same precursor 
as strigolactones and that this 
hormone was indeed strigolactone, or 
strigolactone-derived.
How are they made and regulated? 
Strigolactones are derived from 
ß-carotene which, based on 
Quick guide studies in model species of higher plants, is acted upon by sequential 
enzymatic steps including a 
carotenoid isomerase, two carotenoid
cleavage dioxygeneses, and a 
cytochrome P450 monooxygenase 
named MAX1. Carlactone (Figure 
1A) is a common intermediate 
of strigolactone biosynthesis in 
plants and is produced upstream 
of MAX1. Downstream of MAX1, 
there is considerable diversity in 
strigolactone structures among 
different species (Figure 1B). Major 
open questions in this field are 
what additional enzymes, if any, 
are required downstream of MAX1 
proteins in different species, what is 
the molecular cause of the structural 
diversity of strigolactones and what 
is the consequence or benefit of 
this for their signalling and function 
as hormones and signals in the 
rhizosphere? 
In most species, transcription 
of genes encoding most of the 
strigolactone biosynthesis enzymes is
feedback regulated and regulated by 
the plant hormone auxin. Depending 
on the species, strigolactone levels 
are also influenced by nutrients, 
particularly phosphate. 
Where are they produced? 
Strigolactones are not just made in 
roots. The biosynthetic genes are 
expressed strongly also in stems and 
grafting experiments indicate that 
shoot production of strigolactones 
might be most effective at inhibiting 
branching. About half of the 
biosynthetic pathway occurs in 
the plastid and subsequent steps 
produce molecules that can move 
over long distances, although 
apparently only in the direction of root
to shoot.
What do they do? Like other 
plant hormones, strigolactones 
are involved in a complex whole-
plant signalling network involving 
regulation of and by other plant 
hormones, light and nutrients. 
Some researchers believe that 
strigolactones may have evolved 
as a hormone for mediating whole-
plant responses to nutrient status 
and environmental stress. For 
many species grown under low 
phosphate conditions, strigolactone 
exudation from roots is very high 
and encourages the symbiosis 
with AM fungi. At the same time, 
 
 
 
 
 
 
